GlassScriptPhysician profile
Elisha Collins
NPI 1811437866
$7,499.59
in general payments reported to CMS, 2019-2025
24 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,145 · 2022: $2,143 · 2023: $1,910 · 2024: $2,088 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,735 · Education: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,734.61 |
| Education | $476.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,357.76 | 2021-2024 | |
| Genzyme Corporation | $1,051.44 | 2021-2025 | |
| Pfizer INC. | $891.90 | 2021-2025 | |
| Janssen Biotech, INC. | $708.22 | 2021-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $648.55 | 2021-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $528.89 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $442.62 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $408.08 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $260.89 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $220.20 | 2021-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $188.94 | 2024 | |
| Galderma Laboratories, L.P. | $167.48 | 2022-2024 | |
| Lilly USA, LLC | $144.27 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $130.50 | 2022-2024 | Opzelura |
| Itamar Medical INC | $98.22 | 2023 | Watchpatone |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $43.53 | 2021-2024 | Immunocap |
| Journey Medical Corporation | $39.08 | 2022-2023 | |
| Organon LLC | $36.95 | 2025 | |
| Mallinckrodt Hospital Products INC. | $34.60 | 2024 | Acthar |
| Dermira, INC. | $24.62 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.54 | 2024 | |
| Paratek Pharmaceuticals, INC. | $18.86 | 2025 | Nuzyra |
| Dermavant Sciences, INC. | $17.86 | 2023 | Vtama |
| Verrica Pharmaceuticals INC. | $16.59 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisha Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.